{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-041294","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.799330+00:00","generated_at":"2026-06-11T18:02:47.441007+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ARS Pharma reports Q2 net loss $17.4M; neffy PDUFA date Sept 19, 2023","bullets":["Cash, equivalents and short-term investments $252.2M as of June 30, 2023, funding at least three years.","R&D expense $7.3M, G&A $13.3M, net loss $17.4M for Q2 2023.","PDUFA target action date for neffy NDA (intranasal epinephrine) set for September 19, 2023.","FDA Advisory Committee voted 16:6 adults, 17:5 children for favorable benefit-risk profile.","Commercial preparations underway; hiring 115 field reps; European MAA decision expected by year end 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-041294","json":"https://secwatch.observer/filing/0000950170-23-041294.json","markdown":"https://secwatch.observer/filing/0000950170-23-041294.md","text":"https://secwatch.observer/filing/0000950170-23-041294.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000095017023041294/0000950170-23-041294-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000095017023041294/spry-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:02:47.441007+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6b08daaa4a5a3c2b8a0c595ea6aca56863da378e","claim":"ARS Pharmaceuticals, Inc. reported the three and six months ended June 30, 2023 results: net income Net loss was $17.4 million for the quarter ended June 30, 2023..","evidence_excerpt":"On August 10, 2023, ARS Pharmaceuticals, Inc. (the “Company”) announced its financial results for the three and six months ended June 30, 2023 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000095017023041294/0000950170-23-041294-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and six months ended June 30, 2023"},{"label":"Net income","value":"Net loss was $17.4 million for the quarter ended June 30, 2023."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}